Parsabiv

Chemical Nameetelcalcetide
Dosage FormInjection (intravenous; 2.5 mg/0.5 ml, 5 mg/ml, 10 mg/2 ml)
Drug ClassReceptor agonists
SystemEndocrine
CompanyKAI Pharmaceuticals, Inc.
Approval Year2017

Indication

  • To treat secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Parsabiv (Etelcalcetide) Prescribing Information 2017KAI Pharmaceuticals, Inc., Thousand Oaks, CA